[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osas-obstructive-sleep-apneas-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osas-obstructive-sleep-apneas-syndrome":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100630896","immune-status-and-disease-control-of-inflammatory-airway-diseases-100630896",false,"NCT07493629","Immune Status and Disease Control of Inflammatory Airway Diseases","Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases","ISDC-IAD","Inclusion Criteria\n\n1. Age ≥18 years (≥40 years for COPD patients).\n2. Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria.\n3. PRISm patients (post-BD FEV1\u002FFVC ≥70% and FEV1 \\\u003C80% predicted)\n4. Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms.\n5. Healthy controls: normal lung function, FeNO \\\u003C20 ppb, total IgE \\\u003C100 IU\u002FmL, no chronic disease, smoking \\\u003C10 pack-years, no immunosuppressant use within 3 months.\n\nExclusion Criteria\n\n1. Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer.\n2. Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy.\n3. Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy)\n4. Pregnant or lactating women.\n5. Patients with poor compliance as judged by the investigators.\n6. Subjects currently participating in other clinical studies.",true,"ALL","18 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:\n\n1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.\n\nParticipants will:\n\n1. Answer questions about their health and symptoms.\n2. Give blood samples\n3. Have lung function tests and other standard check-ups.\n4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.",[26,27,28,29,30,31],"Airway Inflammation","Chronic Obstructive Pulmonary Disease (COPD)","Asthma (Diagnosis)","Bronchiectasis","OSAS (Obstructive Sleep Apneas Syndrome)","Allergic Bronchopulmonary Aspergillosis (ABPA)",[33,34,35,36,37],"Airway Inflammatory Diseases","Immunophenotyping","Metabolomics","Cytometry by Time-of-Flight","High-dimensional immune profiling","RECRUITING","2026-03-23",{"date":41,"type":42},"2026-03-25","ACTUAL",{"date":44,"type":42},"2025-08-01",{"date":46,"type":22},"2026-08-01",{"name":48,"class":49},"First Affiliated Hospital of Ningbo University","NETWORK",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":50},"100628260","the-use-of-remimazolam-versus-dexmedetomidine-for-patients-receiving-drug-induced-sleep-endoscopy-100628260","NCT07459322","The Use of Remimazolam Versus Dexmedetomidine for Patients Receiving Drug-Induced Sleep Endoscopy","Inclusion Criteria:\n\n* Patients age \\> 18 years old\n* American Society of Ansthesiologists functional class \\\u003C III\n* Schedule to receive DISE exam for evaluation of OSAS\n\nExclusion Criteria:\n\n* Patient refusal\n* Allergic to experimental medication\n* History of central nervous system diseases\n* History of psychiatric diseases\n* Pregnancy\n* Severe, uncontrolled systemic diseases",{"count":58,"type":22},60,"INTERVENTIONAL",[61],"NA","This study seeks to compare the clinical efficacy and safety of the novel sedative Remimazolam with Dexmedetomidine in Drug-Induced Sleep Endoscopy (DISE), evaluating their performance in sedation depth stability, incidence of adverse events, and postoperative recovery time, thereby providing evidence-based guidance for sedative selection in OSA patients. Additionally, it aims to develop a model for predicting upper airway obstruction sites by analyzing Polysomnography (PSG) data with artificial intelligence, enhancing diagnostic accuracy and treatment decision-making efficiency for Obstructive Sleep Apnea (OSA) to optimize clinical management.",[30,64,65],"DISE","Sedation",[67,64,65,68,69],"OSAS","Remimazolam","Dexmedetomidine","NOT_YET_RECRUITING","2026-03-04",{"date":73,"type":42},"2026-03-09",{"date":75,"type":22},"2026-04-15",{"date":77,"type":22},"2027-12-31",{"name":79,"class":80},"Fu Jen Catholic University Hospital","OTHER",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100590780","the-outcome-of-chronic-kidney-disease-patients-with-obstructive-sleep-apnea-syndrome-100590780","NCT06971874","The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome","The Epidemiological Patterns of Obstructive Sleep Apnea Syndrome in Patients With Chronic Kidney Disease and Its Impact on Renal Prognosis","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form;\n\n  * Aged ≥ 18 years and \\\u003C 75 years;\n  * Patients with CKD stages 3-4, with an eGFR of 15-60 ml\u002Fmin\u002F1.73m² calculated using the CKD-EPI formula for at least 3 months.\n\nExclusion Criteria:\n\n* Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment;\n\n  * Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.;\n  * Patients with other severe comorbidities: Severe heart failure (NYHA class III or IV); Myocardial infarction, unstable angina, or stroke within the past 3 months; Severe arrhythmias requiring medication or device therapy; Respiratory diseases, including COPD, asthma, thoracic deformities, etc.; Neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.; Active liver disease or severe hepatic insufficiency; Psychiatric conditions, including depression, anxiety disorders, etc.; History of malignancy within the past 5 years (except cured basal cell carcinoma); Uncontrolled hyperthyroidism;\n  * Patients who underwent surgery or had acute infections within the past 3 months;\n  * Current heavy alcohol consumption:Females: \\>3 drinks\u002Fday or \\>7 drinks\u002Fweek; Males: \\>4 drinks\u002Fday or \\>14 drinks\u002Fweek (1 standard drink = 14g of alcohol)\n  * Current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.;\n  * Females who are pregnant or lactating at screening or baseline;\n  * Inability to comply with the study due to: Low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures (e.g., follow-up);\n  * Deemed unsuitable for participation by the investigator's judgment.","75 Years",{"count":90,"type":22},356,"Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular disease risk, OSA may worsen renal function and diminish quality of life, making its understanding critical for CKD patient health.\n\nThis study will establish a large, long-term cohort of non-dialysis CKD patients to identify OSA risk factors, explore OSA's association with adverse renal outcomes, and determine OSA prevalence and epidemiological characteristics within the CKD population. The findings will provide a scientific foundation for early OSA identification, diagnosis, and intervention in CKD patients.",[93,30],"Chronic Kidney Diseases","2025-11-14",{"date":96,"type":42},"2025-11-17",{"date":98,"type":42},"2025-07-17",{"date":100,"type":22},"2029-12-31",{"name":102,"class":80},"Nanfang Hospital, Southern Medical University"]